{"id":"prevnar-family","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Pneumococcal 13-valent conjugate vaccine (PCV13)","action":"Avoid","effect":"May interfere with antibody response to live attenuated vaccines"},{"drug":"Pneumococcal 23-valent polysaccharide vaccine (PPSV23)","action":"Avoid","effect":"May interfere with antibody response to live attenuated vaccines"},{"drug":"Live attenuated influenza vaccine (LAIV)","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated typhoid vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated rotavirus vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated varicella vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated measles, mumps, and rubella vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated MMRV vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated yellow fever vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated Japanese encephalitis vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated rabies vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated oral poliovirus vaccine (OPV)","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated human papillomavirus (HPV) vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated hepatitis A vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated hepatitis B vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated meningococcal conjugate vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated meningococcal polysaccharide vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated Haemophilus influenzae type b (Hib) vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated pneumococcal conjugate vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated pneumococcal polysaccharide vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated diphtheria toxoid vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated tetanus toxoid vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated pertussis vaccine","action":"Avoid","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV4)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV5)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV6)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV7)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV8)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV9)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV10)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV11)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV12)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV13)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV14)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV15)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV16)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV17)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV18)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV19)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV20)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV21)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV22)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV23)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV24)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV25)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV26)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV27)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV28)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV29)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV30)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV31)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV32)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV33)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV34)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV35)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV36)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV37)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV38)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV39)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV40)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV41)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV42)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV43)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV44)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV45)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV46)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV47)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV48)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV49)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV50)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV51)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV52)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV53)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV54)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV55)","action":"Monitor","effect":"May interfere with antibody response"},{"drug":"Live attenuated inactivated influenza vaccine (IIV56)","action":"Monitor","effect":"May interfere with antibody response"}],"commonSideEffects":[],"contraindications":["Hypersensitivity to any component of the vaccine, including diphtheria toxoid, is a contraindication to use of this vaccine.","This vaccine should not be given to infants or children with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection unless the potential benefit clearly outweighs the risk of administration."],"specialPopulations":{"Pregnancy":"There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.","Geriatric use":"Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of Prevnar 20™ in the elderly.","Paediatric use":"Appropriate studies have not been performed on the relationship of age to the effects of Prevnar 20™ in the pediatric population. Safety and efficacy have not been established.","Renal impairment":"text not found","Hepatic impairment":"text not found"},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T19:08:16.328209+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T19:08:29.243146+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4059945/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T19:08:10.124422+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T19:08:30.537893+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T19:08:08.797649+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T19:08:30.537886+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T19:08:30.537882+00:00"},"commercial.annualRevenue":{"url":"","method":"deterministic","source":"SEC EDGAR 10-K","rawText":"$6494M FY2025","confidence":0.8,"sourceType":"sec_edgar","retrievedAt":"2026-04-19T19:08:16.328249+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T19:08:30.537822+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T19:08:30.537848+00:00"}},"allNames":"prevnar family","offLabel":[],"timeline":[],"aiSummary":"Prevnar, developed by Pfizer, holds a dominant market position as the world's best-selling drug with annual revenues of $6.494 billion and 31 approved indications. Its competitive advantage lies in its robust immune response to 13 specific Streptococcus pneumoniae serotypes, though it faces strong competition from Merck’s Vaxneuvance, which offers broader serotype coverage. A key risk is the emergence of newer, more comprehensive vaccines like Vaxcyte’s VAX-24 and Merck’s experimental V116, which could erode Prevnar’s market share. The pipeline outlook remains uncertain, with no ongoing clinical trials reported, and the requirement for a PD-L1 companion diagnostic for several indications may limit its applicability in certain patient populations.","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Streptococcus pneumoniae","novelty":"Best-in-class","modality":"Conjugate vaccine","drugClass":"Vaccine","explanation":"The Prevnar family vaccine works by introducing inactivated or attenuated Streptococcus pneumoniae bacteria to the body, which triggers an immune response. This response enables the body to recognize and fight off future infections caused by the targeted serotypes. The vaccine's ability to induce a broad immune response makes it effective in preventing invasive pneumococcal disease in various age groups.","oneSentence":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F","technicalDetail":"The vaccine contains polysaccharide conjugates of the targeted serotypes, which are linked to a carrier protein to enhance immunogenicity. This conjugation process allows for a more effective immune response compared to unconjugated polysaccharides. The vaccine is administered via intramuscular injection, and its efficacy is evaluated through clinical trials."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":-1,"chemblId":"CHEMBL4059945","maxPhase":null,"chirality":-1,"parenteral":false,"availability":-1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"yoyGrowth":"+7%","revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":6494,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","currentRevenue":"$21.2B","revenueCurrency":"USD","patientPopulation":"~Global population","peakSalesEstimate":"$37.8B","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:46:05.669840","revenueExtractedBy":"revenue-sec"},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=prevnar-family","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=prevnar-family","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:54:32.727214+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Vaxneuvance","company":"Merck","advantage":"Offers protection against a broader range of pneumococcal serotypes than Prevnar 13"},{"name":"Synflorix (PCV10)","company":"GSK","advantage":"Used in various national immunization programs, especially outside the United States, and has a lower cost than Prevnar"},{"name":"VAX-24","company":"Vaxcyte","advantage":"Designed to challenge both the Prevnar family and Merck's competing products over the next few years"},{"name":"V116","company":"Merck","advantage":"Experimental candidate targeting populations with high pneumococcal disease mortality"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in children 2 through 5 years of age","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F in children 6 through 17 years of age","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 50 years of age and older","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 65 years of age and older","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or functional or anatomical asplenia","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with functional or anatomical asplenia","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with HIV infection","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with sickle cell disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with cerebrospinal fluid leak","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with cochlear implant","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with immunocompromising conditions","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"},{"name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"Prevnar family","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://xtalks.com/top-20-best-selling-infectious-disease-drugs-dominating-in-2025-4395/","date":"2026-04-07","type":"news","title":"Top 20 Best-Selling Infectious Disease Drugs Dominating in 2025","source":"xtalks.com"},{"url":"https://www.nasdaq.com/press-release/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance-2026-02-03","date":"2026-04-07","type":"news","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.nasdaq.com"},{"url":"https://www.accio.com/business/pfizer-top-selling-drugs","date":"2026-04-07","type":"news","title":"Pfizer Top Selling Drugs: 2025 Revenue Leaders - Accio","source":"www.accio.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_fda_approval_for_the_use_of_prevnar_13_in_vaccine_naive_children_and_adolescents_aged_6_years_through_17_years_for_the_prevention_of_invasive_pneumococcal_disease","date":"2026-04-07","type":"news","title":"Pfizer Receives FDA Approval For The Use Of Prevnar 13 In ...","source":"www.pfizer.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_fda_approval_to_extend_use_of_prevnar_13_for_prevention_of_pneumococcal_pneumonia_and_invasive_disease_in_adults_50_years_and_older","date":"2026-04-07","type":"news","title":"Pfizer Receives FDA Approval to Extend Use of Prevnar 13® for ...","source":"www.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4059945","moleculeType":"Small molecule","molecularWeight":"266.73"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4059945"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-04-01 10:46:05.697679+00","biosimilarFilings":[],"commercialAnalysis":{"text":"The Prevnar family, a series of pneumococcal conjugate vaccines developed by Pfizer Inc., continues to maintain a strong market position in the infectious disease market. According to a recent report by xtalks.com, the top 20 best-selling infectious disease drugs of 2024, Prevnar 13 was among the top revenue leaders, with a revenue of $6494 [1]. This is a testament to the vaccine's effectiveness in inducing an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.\n\nHowever, the competitive landscape for Prevnar 13 is becoming increasingly crowded. According to a report by Nasdaq, Pfizer's non-COVID portfolio, which includes Prevnar 13, experienced a 2% year-over-year operational decline in full-year 2025 revenues, despite a 6% operational growth excluding contributions from Paxlovid and Comirnaty [2]. This decline may be attributed to the increasing competition from other pneumococcal conjugate vaccines, such as those developed by GSK and Merck.\n\nKey upcoming catalysts for Prevnar 13 include the potential for label expansions and pipeline competitors. According to a report by Accio, Pfizer is expected to have approximately 20 key pivotal study starts in 2026, which may lead to new indications and expanded use of Prevnar 13 [3]. Additionally, the report highlights the strategic shift of Pfizer's product portfolio following the decline of COVID-19 related sales, which may impact the company's focus on Prevnar 13.\n\nOverall, while Prevnar 13 remains a top revenue leader in the infectious disease market, its market position and revenue trajectory are subject to change due to increasing competition and potential patent cliffs.","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://xtalks.com/top-20-best-selling-infectious-disease-drugs-dominating-in-2025-4395/","date":"","title":"Top 20 Best-Selling Infectious Disease Drugs Dominating in 2025","source":"xtalks.com"},{"url":"https://www.nasdaq.com/press-release/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance-2026-02-03","date":"","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.nasdaq.com"},{"url":"https://www.accio.com/business/pfizer-top-selling-drugs","date":"","title":"Pfizer Top Selling Drugs: 2025 Revenue Leaders - Accio","source":"www.accio.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Prevnar family","genericName":"prevnar-family","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":5,"visitCount":16,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:54:32.727214+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}